Assessing the effect of PRP addition to facial micro-lipofilling for patients suffering from Scleroderma: A prospective routine care analysis

Ann Chir Plast Esthet. 2023 Apr;68(2):152-161. doi: 10.1016/j.anplas.2022.07.016. Epub 2022 Aug 18.

Abstract

Background: Combining fat graft with platelet derived products is now common practice in regenerative surgery. We proposed to assess the safety and efficacy of Platelet-Rich Plasma (PRP) addition to a micro-lipofilling protocol for facial treatment of patients suffering from Systemic Sclerosis (SSc).

Objective: Main objective was to evaluate the improvement of the Mouth Handicap In Systemic Sclerosis (MHISS) scale score at 6 months post-therapy.

Method: Included SSc patients had a MHISS score equal or up to 20. Surgery was performed under general anesthesia. Micro-fat and PRP (CCA-NA from DEPA Classification) were mixed in a 70/30 ratio, before injection in peri-oral sites according to a specific protocol. Efficacy criteria were recorded at baseline, 3 and 6 months. Moreover, we compared this cohort (current study) to a former (2015) non-enriched micro-lipofilling cohort in the same indication, using the same protocol.

Results: Thirteen women patients with mean age of 53.2 years (±14.3) have been included. At baseline, mean MHISS score was 29.5 (±8.7) and significantly decreased to 22.5 (±7.8) at 6 months (P=0.016), corresponding to a 22.0% of improvement from baseline, with a mean decrease of 6.5 points (±7.5) at 6 months. Patients received a mean volume of 30.8ml PRP-micro-fat (±8.1ml).

Conclusion: PRP addition appeared beneficial, however, controlled studies are required to determine its superiority to facial micro-lipofilling.

Keywords: Autologous adipose tissue; Mouth Handicap In Systemic sclerosis Scale (MHISS); Plasma Riche en Plaquettes; Platelet-Rich-Plasma; Sclérodermie systémique; Systemic sclerosis; Tissu adipeux autologue.

MeSH terms

  • Face / surgery
  • Female
  • Humans
  • Middle Aged
  • Mouth
  • Platelet-Rich Plasma*
  • Prospective Studies
  • Scleroderma, Systemic* / surgery
  • Treatment Outcome